Abstract
A woman with lung cancer in whom the usual toxicities from erlotinib did not develop at the standard dose had a tumor response and side effects when the erlotinib dose was increased. Furthermore, the erlotinib dose had to be reduced when fenofibrate was stopped.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
